AMYT - Earnings announcements

Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT. Amryt will host a conference call and webcast for analysts and investors on November 3, 2022 at 0830 ET/1230 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj Telephone Dial in details: Standard International Number + 39 (0) 02 802 0911 United States +1

Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2022 will be released on Thursday, August 4, 2022 at 0700 ET/1200 BST. Amryt will host a conference call and webcast for analysts and investors on August 4, 2022 at 0830 ET/1330 BST. Webcast Player URL: https://edge.media-server.com/mmc/p/ef7uj5u8 Telephone Dial in details: United States +1 646 307 1963United Kingdom +44 (0) 203 481 4247Ireland +353 (1) 582 2023Confirmation Code9953783 A playback facility

Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c

Amryt to Report Q1 2022 Results on May 4, 2022 DUBLIN, Ireland, and Boston MA, April 14, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the first quarter 2022 will be released on Wednesday, May 4, 2022 at 0700 ET/1200 BST. Amryt will host a conference call and webcast for analysts and investors on May 4, 2022 at 0830 ET/1330 BST. Webcast Player URL: https://edge.media-server.com/mmc/p/uso54daj Telephone Dial in details: United States +1 646 741 3167 United Kingdom +44 (0) 207 192 8338 Ireland +353 (1

Amryt Announces 22% growth in FY 2021 Revenues to $222.5M  Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8th consecutive quarter of positive EBITDA generation 32% YoY growth in metreleptin revenues Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET  Global NET market opportunity is estimated to be approx. $1.9bn* Conference call and webcast today at 0830 EST / 1330 GMT DUBLIN, Ireland, and Boston MA, March 9, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring

Amryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the fourth quarter 2021 and full year ended December 31, 2021 will be released on Wednesday, March 9, 2022 at 0700 EST / 1200 GMT. Amryt will host a conference call and webcast for analysts and investors on March 9 at 0830 EST / 1330 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/ebranod7      Telephone Dial in details: United States +1 646 741 3